PAOLA LUNA: Open Payments
NPI 1770142507 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,867 in 128 payments from 18 companies in 2025. Trend: 2023 $2,213 · 2024 $2,659 · 2025 $2,867
Food & beverage: $2,867
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $417 |
| Bayer Healthcare Pharmaceuticals Inc. | 17 | $363 |
| Novo Nordisk Inc | 8 | $250 |
| Abbott Laboratories | 4 | $250 |
| Lilly USA, LLC | 20 | $244 |
| Ardelyx, Inc. | 9 | $231 |
| ABBVIE INC. | 9 | $210 |
| GlaxoSmithKline, LLC. | 11 | $189 |
| Madrigal Pharmaceuticals | 7 | $173 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $136 |
Products named: Kerendia, FARXIGA, MOUNJARO, IBSRELA, ESPRIT, TRELEGY ELLIPTA, REZDIFFRA, Ozempic.
Industry payments across TX — which companies pay providers there.
